TAG:
genomics
Ampersand Buys Calloway Labs, Enters Pain Management Market
URINE DRUG TESTING for pain management may be a challenging business for clinical labs given that compliance officers in the states and in the federal government have successfully pursued lab compliance abuses in this line of business in recent years. Now comes news that private equity firm …
Sonic Healthcare, Bio-Reference Report Financial Performance
IN RECENT WEEKS, two of the nation’s larger public laboratory companies issued their earnings reports. In both cases, revenue growth was strong, a distinct difference from the recent financial performance of their two largest lab public company competitors. It was on August 21, 2012, when …
Pathologists in China, U.S. Linked By Digital Pathology
CEO Summary: It is one of the first clinical collaborations of this type to be anchored by use of digital pathology. Pathologists at the medical schools of the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and the University of California Los Angeles (UCLA) are exc…
April 23, 2012 “Intelligence: Late Breaking Lab News”
“Innovator of the Year” honors were recently bestowed on Robin Felder, Ph.D., who is Professor of Pathology and Associate Director of Clinical Chemistry at the University of Virginia School of Medicine in Charlottesville. Felder was selected as the winner of the 2012 Edlich-Hen…
Exome Sequencing Next “Big Thing” for Diagnosis
CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—…
Rosetta Genetics, Aureon Biosciences, Plus Diagnostics, Atherotech, Sequenom
ROSETTA GENOMICS TO LAY OFF 35 EMPLOYEES TO CUT EXPENSES AND SHIFT MORE FUNDING toward sales of its proprietary molecular tests, Rosetta Genomics says it will eliminate 35 jobs. The company, based in Israel, operates a clinical laboratory in Philadelphia, Pe…
Thermo Fisher, Intrinsic Bioprobes, Kaiser Permanente, UCSF, CLMA, ASCLS
THERMO FISHER BUYS INTRINSIC BIOPROBES, CONTINUES BUYING SPREE IT’S ANOTHER ACQUISITION FOR Thermo Fisher Scientific, Inc., of Waltham, Massachusetts. It purchased Intrinsic Bioprobes, Inc., of Rochester, New York, earlier this month. A m…
March 21, 2011 “Intelligence: Late Breaking Lab News”
Regulation of genetic tests by the Food and Drug Administration (FDA) continues to move forward. Earlier this month, an FDA advisory panel conducted hearings on this subject. The Molecular and Clinical Genetics Panel of FDA’s Medical Devices Advisory Committee discussed several asp…
December 6, 2010 “Intelligence: Late Breaking Lab News”
With its announcement last month of an agreement to acquire US Oncology for $2.16 billion, McKesson Corporation has greatly expanded its presence in oncology. US Oncology provides practice management services in support of 1,392 oncologists who work at 517 locations …
“Primary-Care Pathology” One Goal at Beth Israel
CEO SUMMARY: In a pioneering collaboration, the pathology department at Beth Israel Deaconess Medical Center in Boston, Massachusetts, will work with GenomeQuest, Inc., to perform whole genome sequencing of tumor specimens. GenomeQuest will handle sequencing, assembly, and annota…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.